Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019
April 22 2019 - 8:30AM
Atossa Genetics Inc. (NASDAQ:
ATOS), a
clinical-stage biopharmaceutical company developing novel
therapeutics and delivery methods for breast cancer and other
breast conditions, today announced that Steven C. Quay, M.D.,
Ph.D., Atossa’s President and CEO, will present at the Precision:
Breast Cancer World R&D Summit at 2:00 pm ET on April 25th. The
conference will be held at the Courtyard by Marriott Boston
Downtown from April 24 - 25, 2019.
Dr. Quay’s presentation is titled “A Twenty-First Century
Approach: From Primary Prevention to Intraductal Immunotherapy,”
and will be given during the Novel Approaches in Breast Cancer Drug
R&D portion of the conference.
About Precision: Breast Cancer World R&D
Summit
The Precision Breast Cancer World R&D Summit is an
exclusive, annual biopharma summit providing insights into the
research and development of cutting-edge treatments for Breast
Cancer and a networking forum for precision medicine leaders in
this space. From therapeutics to diagnostics, the summit brings
together scientists and business leaders from pharma, biotech and
academia, using extensive networking sessions to forge meaningful
collaborations. The discussion and presentations are based around
the latest trends in personalized medicine, using case studies
covering early discovery to clinical development.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage biopharmaceutical
company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more information,
please
visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, potential market sizes for Atossa's drugs under
development and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc. Kyle Guse CFO and General Counsel Office:
866 893-4927 kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott Gordon CoreIR 377 Oak Street Concourse 2 Garden City, NY
11530 Office: 516 222-2560 scottg@CoreIR.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024